1 day Ago By ABMN Staff
Evolus, Inc. ( NASDAQ:EOLS – Get Free Report )’s share price fell 2.9% on Wednesday .
The stock traded as low as $16.26 and last traded at $16.40.
205,687 shares were traded during trading, a decline of 65% from the average session volume of 579,662 shares. The stock had previously closed at $16.89.
Analysts Set New Price Targets Several research firms have recently weighed in on EOLS. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Friday, September 13th.
Barclays boosted their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th.
Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Monday. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, August 1st.
Get Our Latest Report on Evolus Evolus Stock Down 4.0 % Evolus ( NASDAQ:EOLS – Get Free Report ) last posted its earnings results on Wednesday, July 31st. The company reported ($0.
14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02).
The company had revenue of $66.91 million for the quarter, compared to the consensus estimate of $65.06 million.
As a group, equities analysts predict that Evolus, Inc. will post -0.64 earnings per share for the current year.
Insiders Place Their Bets In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.
48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96.
The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink . In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.
98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.
96. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink . Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction dated Friday, August 30th.
The stock was sold at an average price of $15.85, for a total transaction of $89,251.35.
Following the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The disclosure for this sale can be found here .
Insiders own 6.10% of the company’s stock. Institutional Inflows and Outflows Several hedge funds have recently modified their holdings of the stock.
California State Teachers Retirement System grew its stake in Evolus by 1.6% during the 1st quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock valued at $674,000 after acquiring an additional 739 shares in the last quarter.
ProShare Advisors LLC grew its stake in Evolus by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock valued at $162,000 after acquiring an additional 1,035 shares in the last quarter.
Arizona State Retirement System grew its stake in Evolus by 9.4% during the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after acquiring an additional 1,253 shares in the last quarter.
Price T Rowe Associates Inc. MD grew its stake in Evolus by 4.3% during the 1st quarter.
Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock valued at $559,000 after acquiring an additional 1,637 shares in the last quarter. Finally, Tradition Wealth Management LLC grew its stake in Evolus by 44.
8% during the 4th quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock valued at $84,000 after acquiring an additional 2,475 shares in the last quarter. Institutional investors and hedge funds own 90.
69% of the company’s stock. About Evolus ( Get Free Report ) Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Read More Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter ..
